Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Hurricane Maria Continues to Wreak Havoc on the Medical Industry

Though it has been nearly four months since Hurricane Maria made landfall in Puerto Rico, the effects continue to devastate the medical industry both on the island and the mainland. The power grid on the island remains mostly inoperable, leaving Puerto Rico’s many medical equipment manufacturing plants unable to operate. The United States Food and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Though it has been nearly four months since Hurricane Maria made landfall in Puerto Rico, the effects continue to devastate the medical industry both on the island and the mainland. The power grid on the island remains mostly inoperable, leaving Puerto Rico’s many medical equipment manufacturing plants unable to operate.

The United States Food and Drug Administration (FDA) has confirmed that the U.S. territory of Puerto Rico typically produces about $40 billion worth of pharmaceuticals each year. This amounts to more pharmaceutical production than any one of the 50 states, any other U.S. territory, or any single foreign country. Unfortunately, these productive manufacturing facilities have mostly shut down since Hurricane Maria hit land nearly four months ago, and the plants that are in operation continue to rely on generators.

Three of the affected manufacturing plants are home to Baxter, one of the most significant suppliers of IV bags. All three of Baxter’s plants on the island were forced to stall manufacturing. While two stations are now up and running on generators, the other remains closed.

According to the New York Times, about 10% of the drugs that Americans consume every day are made in Puerto Rico. While the island continues to recover from the devastating hurricane, medical professionals on the mainland should expect low supply, back orders, and price increases.

Unfortunately, these drug shortages could affect Accutome by Keeler and its customers. Ophthalmology offices should be aware of this backup and prepare accordingly. These professionals should expect Accutome and other providers to be out of certain products like morphine, IV solutions, mesh, surgical scalpels, and more. While the provider works hard to secure these products for customers.

The FDA is working with the manufacturers in Puerto Rico to get production back on track. The agency is currently monitoring a total of 90 products in hopes of stopping shortages before they become critical. The administration is also working with Puerto Rico to get manufacturing back on track.

“We continue to work closely with federal and Puerto Rican authorities to address the needs of manufacturers on the island for power and other resources. … Mitigating medical product shortages will require a sustained effort by the industry, the agency, and other partners as we work with manufacturers to return to production levels that adequately meet the needs of patients,” FDA Commissioner Scott Gottlieb, MD, said in a statement.

Thanks to generous tax incentives, Puerto Rico is home to many big-name manufacturers such as Johnson & Johnson, Pfizer, and Abbott Medical Optics. However, because only about half of these manufacturers are producing right now, medical professionals across the United States are destined to feel the shortage.

Since 2014, the FDA has been monitoring Puerto Rico for potential drug shortages. But Hurricane Maria turned a potential problem into a significant and immediate emergency. This shortage has made it difficult for cancer patients to receive proper care because Baxter makes the saline bags used for treatments. Furthermore, care of premature babies has been placed in jeopardy due to the shortage.

Accutome by Keeler is in its fourth decade of operation and will not allow this hurricane to end its reputation as a leader in the ophthalmic industry. With superior customer service, quality, and innovation, the company will continue to serve its customers through this crisis. Customers should feel free to contact their representatives with any questions they may have.

Accutome by Keeler stands with the people of Puerto Rico, its customers, and its commitment to service. While Hurricane Maria may have disrupted supplies, customers will not see a disruption in the service they have come to expect.

Read more at accutome.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512